首页> 外文期刊>International Journal of Cancer =: Journal International du Cancer >Gender and ethnic differences in incidence and survival of lymphoid neoplasm subtypes in an Asian population: Secular trends of a population-based cancer registry from 1998 to 2012
【24h】

Gender and ethnic differences in incidence and survival of lymphoid neoplasm subtypes in an Asian population: Secular trends of a population-based cancer registry from 1998 to 2012

机译:亚洲人群淋巴瘤亚型的发生率和生存率的性别和种族差异:1998年至2012年基于人群的癌症登记册的长期趋势

获取原文
获取原文并翻译 | 示例
           

摘要

Descriptive epidemiology on incidence and survival by lymphoid neoplasm (LN) subtypes using the 2008 World Health Organisation (WHO) classification remained limited in Asia. The aim of this study was to evaluate whether gender and ethnic differences in incidence and survival of LN subtypes existed using the Singapore Cancer Registry (SCR) from 1998 to 2012. We derived age standardised incidence rates (ASIRs) by the direct standardisation method and 5-year relative survival (RSR) by the Ederer II method and period approach. Five-year observed survival (OS) was obtained for each ethnicity. Malays had the highest ASIR of total LNs among the three ethnicities for each time period. The largest increase in 5-year RSR subtypes was follicular lymphoma from 43.8% in 1998-2002 to 82.3% in 2008-2012; followed by chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL) from 48.1% in 1998-2002 to 77.9% in 2008-2012. Although males had higher incidence than females in each time period, females had greater 5-year RSR for follicular lymphoma (89.8% in 2008-2012 for females vs. 76.6% in 2008-2012 for males) and CLL/SLL (78.7% in 2008-2012 for females vs. 76.7% in 2008-2012 for males). All three ethnicities experienced an overall increase in 5-year OS for mature B-cell lymphoma, with Indians experiencing the greatest increase (37.1% in 1998-2002 to 61.1% in 2008-2012), followed by Malays (30.8% in 1998-2002 to 48.7% in 2008-2012) and then Chinese (36.4% in 1998-2002 to 51.3% in 2008-2012). Our study demonstrated that improved mature B-cell lymphoma survival was not only observed in the West, but also in Singapore.
机译:在亚洲,使用2008年世界卫生组织(WHO)分类对淋巴瘤(LN)亚型的发病率和生存率进行描述性流行病学研究仍然很有限。这项研究的目的是评估从1998年至2012年使用新加坡癌症注册(SCR)的LN亚型的发病率和存活率是否存在性别和种族差异。我们通过直接标准化方法得出年龄标准化发病率(ASIR),[5] Ederer II方法和周期方法得出的一年相对生存率(RSR)。每个族裔均获得了五年的观察生存期(OS)。在每个时间段中,马来人在三个族裔中的总LN的ASIR最高。五年期RSR亚型的最大增加是滤泡性淋巴瘤,从1998-2002年的43.8%上升到2008-2012年的82.3%;其次是慢性淋巴细胞性白血病(CLL)/小淋巴细胞性淋巴瘤(SLL),从1998-2002年的48.1%增至2008-2012年的77.9%。尽管男性在每个时期的发病率均高于女性,但女性滤泡性淋巴瘤的5年RSR较高(2008-2012年女性为89.8%,而2008-2012年男性为76.6%)和CLL / SLL(78.7%)。女性为2008-2012年,而男性为2008-2012年的76.7%)。这三个种族的成熟B细胞淋巴瘤的5年OS总体上都有增加,其中印度人的增幅最大(1998-2002年为37.1%,2008-2012年为61.1%),其次是马来人(1998-2002年为30.8%)。 2002年为2008-2012年的48.7%),然后是中文(1998-2002年为36.4%,2008-2012年为51.3%)。我们的研究表明,不仅在西方国家,而且在新加坡,成熟的B细胞淋巴瘤生存率都有所提高。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号